唑尼沙胺添加治疗癫痫患者的有效性及安全性研究  

Efficacy and safety of zonisamide as an add-on treatment for patients with epilepsy

作　　者：杨婷婷 方熙勤 向淇 刘学伍 YANG Tingting;FANG Xiqin;XIANG Qi(Department of Neurology,Qilu Hospital of Shandong University,Jinan 250021,Shandong,China)

机构地区：[1]山东大学齐鲁医院神经内科,山东济南250021 [2]山东第一医科大学附属省立医院神经内科

出　　处：《癫痫与神经电生理学杂志》2023年第3期152-156,175,共6页Journal of Epileptology and Electroneurophysiology(China)

基　　金：山东大学横向项目(6010121099)。

摘　　要：目的评估唑尼沙胺首次与非首次添加治疗癫痫患者的有效性和安全性。方法回顾性分析2022年1-7月期间在山东大学齐鲁医院神经内科门诊就诊且完成了唑尼沙胺添加治疗5个月的癫痫患者的病例资料,选取首次添加与非首次添加患者各42例,共84例患者入组。在完成5个月的添加治疗时评估唑尼沙胺治疗癫痫的有效性及不良反应发生的情况。结果唑尼沙胺作为首次添加治疗5个月时的有效率为79%,非首次添加的有效率为59%,两组患者治疗5个月时的保留率分别为90%和88%,不良反应发生率分别为26%和37%,常见的不良反为头晕、头疼、厌食并体重下降及嗜睡等。结论唑尼沙胺首次添加治疗癫痫的疗效优于非首次添加治疗。Objective To evaluate the efficacy and safety of Zonisamide as a first and non-first add-on treatment for patients with epilepsy.Methods Retrospective analysis was performed on clinical data of outpatients with epilepsy who completed zonisamide as add-on treatment for 5 months in the Department of Neurology,Qilu Hospital of Shandong University from January to July 2022.the first add-on and non first add-on 42 patients respectively,84 patients in total.The efficacy and incidence of adverse reactions of zonisamide at the completion of 5 months of add-on treatment were evaluated.Results The efficiency of zonisamide as a first add-on treatment at 5 months was 79%,and that of zonisamide as a non-first add-on treatment was 59%.The retention rates of zonisamide at 5 months of therapy were 90%and 88%in two groups,respectively,and the adverse reaction rates were 26%and 37%,respectively.The common adverse reactions were dizziness,headache,anorexia,anorexia and weight loss,and drowsiness,etc.Conclusions The efficacy of zonisamide as a first add-on treatment for epilepsy is superior to non-first add-on.

关 键 词：唑尼沙胺 癫痫 抗癫痫发作药物 首次添加 非首次添加 

分 类 号：R971.6[医药卫生—药品] R742.1[医药卫生—药学]